PatientFocus

patientfocus.com

PatientFocus is a medical billing company, that functions as an outsourced extension of our clients’ billing office. We focus exclusively on patient-pay billing – after insurance (or no insurance) and before bad debt – and facilitate patient communications, payment management, and patient financing options. The heart of the PatientFocus solution is the patient. Our unique combination of people, process and platform, and our “Day One” approach results in a highly coordinated, more comprehensive, and extremely efficient outreach program that protects both the patients’ experience and our clients’ brand.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

SONOMA BIOTHERAPEUTICS AND REGENERON ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE TREG CELL THERAPIES FOR AUTOIMMUNE DISEASES

Businesswire | April 03, 2023

news image

Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s industry-leading VelociSuite® technologies for the discovery and characterization of fully human antibodies and T ce...

Read More

Industrial Impact

INTRON CONFIRMS EFFICACY OF CDL200 AGAINST CDI CLINICAL ISOLATES

iNtRON Biotechnology | July 12, 2022

news image

iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients. A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes afte...

Read More

Industrial Impact, Medical

WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN

Willow Biosciences Inc. | December 08, 2022

news image

Willow Biosciences Inc. a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today that it has taken additional steps to focus on near-term revenue generation, protect its balance sheet and reduce its cash burn. Since the early part of the year, the Company has reviewed its market opportunities and its portfolio, using a rigorous evaluation process that has taken into consideration ...

Read More

Cell and Gene Therapy, Industrial Impact

FULGENT GENETICS LAUNCHES MISSION BIO PLATFORM TO BROADEN ACCESSIBILITY OF SINGLE-CELL MULTI-OMICS FOR DRUG DEVELOPMENT AND CLINICAL RESEARCH

Prnewswire | April 12, 2023

news image

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced that it has entered into an agreement with Fulgent Genetics a technology-based company with a well-established clinical diagnostic business and a therapeutic development business. Fulgent Genetics is now able to offer single-cell multi-omics on the Tapestri Platform on its fully customizable menu of services, including whole genome, whole exome, RNA sequencing, tumor profiling, methylation...

Read More
news image

MedTech, Industrial Impact

SONOMA BIOTHERAPEUTICS AND REGENERON ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE TREG CELL THERAPIES FOR AUTOIMMUNE DISEASES

Businesswire | April 03, 2023

Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s industry-leading VelociSuite® technologies for the discovery and characterization of fully human antibodies and T ce...

Read More
news image

Industrial Impact

INTRON CONFIRMS EFFICACY OF CDL200 AGAINST CDI CLINICAL ISOLATES

iNtRON Biotechnology | July 12, 2022

iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients. A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes afte...

Read More
news image

Industrial Impact, Medical

WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN

Willow Biosciences Inc. | December 08, 2022

Willow Biosciences Inc. a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today that it has taken additional steps to focus on near-term revenue generation, protect its balance sheet and reduce its cash burn. Since the early part of the year, the Company has reviewed its market opportunities and its portfolio, using a rigorous evaluation process that has taken into consideration ...

Read More
news image

Cell and Gene Therapy, Industrial Impact

FULGENT GENETICS LAUNCHES MISSION BIO PLATFORM TO BROADEN ACCESSIBILITY OF SINGLE-CELL MULTI-OMICS FOR DRUG DEVELOPMENT AND CLINICAL RESEARCH

Prnewswire | April 12, 2023

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced that it has entered into an agreement with Fulgent Genetics a technology-based company with a well-established clinical diagnostic business and a therapeutic development business. Fulgent Genetics is now able to offer single-cell multi-omics on the Tapestri Platform on its fully customizable menu of services, including whole genome, whole exome, RNA sequencing, tumor profiling, methylation...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us